tadalafil has been researched along with lu 208075 in 46 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (lu 208075) | Trials (lu 208075) | Recent Studies (post-2010) (lu 208075) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 298 | 54 | 227 |
| Protein | Taxonomy | tadalafil (IC50) | lu 208075 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.195 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.6925 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0114 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.17) | 29.6817 |
| 2010's | 33 (71.74) | 24.3611 |
| 2020's | 12 (26.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Boinpally, R; Dufton, C; Harrison, B; Mandagere, A; Spence, R | 1 |
| Belardinelli, L; Liang, F; Shryock, J; Yang, S; Yao, L | 1 |
| Burhenne, J; Haefeli, WE; Riedel, KD; Spalwisz, A; Theile, D; Weiss, J | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Gao, H; Jiang, B; Zhao, W; Zhuang, Y | 1 |
| Hirashiki, A; Kondo, T; Murohara, T | 1 |
| Watanabe, H | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Fujita, J; Fukuda, K; Kataoka, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y; Yamamoto, T | 1 |
| Peacock, AJ; Vizza, CD; Zamboni, W | 1 |
| Barberà, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Gillies, H; Grünig, E; Harris, JH; Hoeper, MM; Langley, J; McLaughlin, VV; Miller, KL; Oudiz, RJ; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiery, JL; Vonk-Noordegraaf, A; White, RJ | 1 |
| Chin, K; Corona-Villalobos, CP; Damico, R; Gashouta, MA; Girgis, RE; Hassoun, PM; Housten, T; Hulme, OL; Khair, R; Kolb, TM; Lechtzin, N; Mathai, SC; Minai, OA; Pisanello, C; Pullins, EH; Sato, T; Tedford, RJ; Torres, F; Zamanian, RT; Zimmerman, SL | 1 |
| Burhenne, J; Enderle, Y; Friedrich, J; Grünig, E; Haefeli, WE; Meid, AD; Wilkens, H | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Foucher, A; Guilleminault, L; Laurent, S; Paganin, F; Poubeau, P | 1 |
| Barberá, JA; Blair, C; Frost, AE; Ghofrani, HA; Harris, JHN; Hoeper, MM; Langley, J; McLaughlin, VV; Miller, KL; Oudiz, RJ; Peacock, AJ; Rosenkranz, S; Rubin, LJ; Simonneau, G; Vachiery, JL; White, RJ | 1 |
| Barberà, JA; Blair, C; Coghlan, JG; Frost, AE; Galiè, N; Ghofrani, HA; Gillies, H; Harris, JHN; Hoeper, MM; Kuwana, M; Langley, J; McLaughlin, VV; Miller, KL; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiéry, JL | 1 |
| Risbano, MG; Rivera-Lebron, BN | 1 |
| Allard, M; Blair, C; Feldman, J; Gillies, H; Keogh, A; Oudiz, RJ; Shapiro, S; Tislow, J; Torres, F | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Chin, K; Damico, R; Girgis, RE; Hassoun, PM; Khair, RM; Kolb, TM; Mathai, SC; Mercurio, V; Minai, OA; Mukherjee, M; Sato, T; Tedford, RJ; Torres, F; Zamanian, RT | 1 |
| Argiento, P; Badagliacca, R; Correale, M; D'Alto, M; Ghio, S; Greco, A; Lo Giudice, F; Paciocco, G; Prediletto, R; Romeo, E; Vizza, CD | 1 |
| Tanabe, N | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Chabot, F; Chaouat, A; Gomez, E; Guillaumot, A; Petitpain, N; Ribeiro Baptista, B; Valentin, S; Yelehé-Okouma, M | 1 |
| Akerström, F; Berenguel Senén, A; Escribano Subías, P; Lázaro Salvador, M; Martinez Mateo, V; Rodriguez Padial, L | 1 |
| Barberá, JA; Blair, C; Frost, AE; Hoeper, MM; Langley, J; Rubin, LJ; Vachiery, JL | 1 |
| Barberá, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Hoeper, MM; Langley, J; McLaughlin, VV; Miller, KL; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiéry, JL | 1 |
| Berni, A; Chen, G; Khindri, S; Okour, M; Port, K; Puri, A; Schneider, I; Tenero, D | 1 |
| Akers, S; Ambrosini, R; Champion, HC; Glickman, S; Haight, D; Lachant, DJ; Meoli, DF; Staicu, S; White, RJ | 1 |
| Barberà, JA; Blair, C; Chakinala, MM; Frost, AE; Ghofrani, HA; Grünig, E; Hoeper, MM; Langley, J; McLaughlin, VV; Oudiz, RJ; Rosenkranz, S; Vonk-Noordegraaf, A; White, RJ | 1 |
| Argiento, P; Badagliacca, R; D'Alto, M; Farro, A; Golino, P; Naeije, R; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Vizza, CD | 1 |
| Barberà, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Hoeper, MM; Langley, J; McLaughlin, VV; Oudiz, RJ; Peacock, AJ; Rosenkranz, S; Rubin, LJ; Simonneau, G; Vachiery, JL | 1 |
| Locatelli, I; Petrovič, M | 1 |
| Blair, C; Coghlan, JG; Kuwana, M; Langley, J; Takahashi, T | 1 |
| El-Hajjar, M; Kumar, S; Zheng, WQ | 1 |
| Argiento, P; Badagliacca, R; Casu, G; Corda, M; Correale, M; D'Alto, M; Ghio, S; Golino, P; Greco, A; Lattanzio, M; Lo Giudice, F; Mercurio, V; Naeije, R; Paciocco, G; Papa, S; Prediletto, R; Romeo, E; Russo, MG; Tayar, A; Vitulo, P; Vizza, CD | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Abston, E; Berman, J; Farber, HW; Govender, P; Hon, S; Lawrence, R | 1 |
| Aurtenetxe Pérez, A; Diago Cabezudo, JI; Escribano Subías, P; Gómez Climent, L; Perelló, MF; Pérez Olivares, C | 1 |
| Broderick, M; Champion, H; Kovacs, G; Mandras, S; Nelsen, A; Olschewski, H; Shen, E | 1 |
| Wang, Y; Zhang, L; Zhang, R | 1 |
| Crook, S; Dorn, ML; Frank, B; Hite, MD; Issapour, A; Ivy, DD; Krishnan, US; Rosenzweig, EB | 1 |
| Abe, K; Hatano, M; Kiely, DG; Koike, G; Takahashi, T; Tunmer, G | 1 |
8 review(s) available for tadalafil and lu 208075
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
Topics: Endothelin A Receptor Antagonists; Exercise Tolerance; Humans; Hypertension, Pulmonary; Pharmacovigilance; Phenylpropionates; Pyridazines; Tadalafil; Treatment Outcome; Vasodilator Agents | 2015 |
Ambrisentan: a review of its use in pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Randomized Controlled Trials as Topic; Tadalafil | 2017 |
Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.
Topics: Antihypertensive Agents; Bayes Theorem; Comparative Effectiveness Research; Drug Combinations; Drug Therapy, Combination; Epoprostenol; Humans; Male; Network Meta-Analysis; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome; Walk Test | 2020 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Humans; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil | 2021 |
Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Epoprostenol; Humans; Nitric Oxide; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil | 2021 |
14 trial(s) available for tadalafil and lu 208075
| Article | Year |
|---|---|
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Topics: Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Carbolines; Drug Combinations; Drug Interactions; Female; Humans; Male; Middle Aged; Phenylpropionates; Phosphodiesterase Inhibitors; Pyridazines; Tadalafil; Vasodilator Agents; Young Adult | 2009 |
Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Carbolines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Outcome Assessment, Health Care; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Tadalafil; Treatment Outcome; Young Adult | 2014 |
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Carbolines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phenylpropionates; Pyridazines; Risk Factors; Tadalafil | 2015 |
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Phenylpropionates; Proportional Hazards Models; Pulmonary Artery; Pyridazines; Tadalafil; Treatment Outcome | 2016 |
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Topics: Adult; Aged; Antihypertensive Agents; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Mixed Connective Tissue Disease; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Scleroderma, Systemic; Tadalafil | 2017 |
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Topics: Adult; Antihypertensive Agents; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Elapid Venoms; Endothelin A Receptor Antagonists; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, C-Type; Outcome Assessment, Health Care; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Survival; Tadalafil; Treatment Outcome | 2017 |
Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Topics: Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Contraction; Observer Variation; Phenylpropionates; Prospective Studies; Pyridazines; Scleroderma, Limited; Tadalafil; Treatment Outcome; Ventricular Dysfunction, Right | 2018 |
Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyridazines; Registries; Risk Assessment; Survival Rate; Tadalafil | 2018 |
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Topics: Aged; Antihypertensive Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyridazines; Tadalafil; Treatment Outcome | 2019 |
A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.
Topics: Biological Availability; Cross-Over Studies; Healthy Volunteers; Humans; Phenylpropionates; Pyridazines; Tadalafil; Therapeutic Equivalency | 2019 |
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil; Vasodilator Agents | 2019 |
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.
Topics: Adult; Aged; Antihypertensive Agents; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Risk Factors; Tadalafil; Vasodilator Agents; Ventricular Dysfunction, Left | 2019 |
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Topics: Adult; Comorbidity; Connective Tissue Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Phenylpropionates; Proportional Hazards Models; Pulmonary Arterial Hypertension; Pyridazines; Risk Assessment; Scleroderma, Systemic; Tadalafil; Treatment Outcome; Vasodilator Agents | 2020 |
Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil; Treatment Outcome | 2022 |
24 other study(ies) available for tadalafil and lu 208075
| Article | Year |
|---|---|
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Topics: Animals; Blotting, Western; Carbolines; Disease Models, Animal; Drug Synergism; Endothelin-1; Hypertension, Pulmonary; Male; Phenylpropionates; Pulmonary Artery; Pyridazines; Rats; Rats, Sprague-Dawley; Tadalafil; Vasoconstriction; Vasodilator Agents | 2012 |
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Topics: Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Bosentan; Carbolines; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Interactions; Endothelin A Receptor Antagonists; Gene Expression Regulation; Genes, Reporter; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Peroxisome-Targeting Signal 1 Receptor; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pregnane X Receptor; Promoter Regions, Genetic; Purines; Pyridazines; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Proteins; RNA, Messenger; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil | 2013 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
Combination therapy adding tadalafil to existing ambrisentan in patients with pulmonary arterial hypertension.
Topics: Carbolines; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Tadalafil | 2014 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prostaglandins; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance; Young Adult | 2015 |
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Topics: Drug Therapy, Combination; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptide, Brain; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prospective Studies; Pyridazines; Scleroderma, Systemic; Stroke Volume; Tadalafil; Ultrasonography; Vascular Resistance | 2015 |
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Topics: Bosentan; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Hypertension, Pulmonary; Limit of Detection; Phenylpropionates; Pyridazines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil; Tandem Mass Spectrometry | 2015 |
Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Drug Approval; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Tadalafil; United States; United States Food and Drug Administration | 2016 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Pulmonary arterial hypertension in adult onset Still's disease: a case report of a severe complication.
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Antirheumatic Agents; Echocardiography; Female; Humans; Hypertension, Pulmonary; Interleukin 1 Receptor Antagonist Protein; Phenylpropionates; Pyridazines; Still's Disease, Adult-Onset; Tadalafil; Tomography, X-Ray Computed; Young Adult | 2016 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Italy; Male; Middle Aged; Phenylpropionates; Pyridazines; Retrospective Studies; Tadalafil; Treatment Outcome; Vascular Resistance | 2018 |
Can results from a Japanese pulmonary hypertension registry have an impact on Western guidelines?
Topics: Angioplasty, Balloon; Cyclic Nucleotide Phosphodiesterases, Type 1; Drug Therapy, Combination; Endarterectomy; Epoprostenol; Genome-Wide Association Study; Hemodynamics; Humans; Hypertension, Pulmonary; Japan; Molecular Targeted Therapy; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Practice Guidelines as Topic; Pulmonary Embolism; Pyridazines; Randomized Controlled Trials as Topic; Registries; Sildenafil Citrate; Tadalafil | 2018 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.
Topics: 4-Aminopyridine; Antihypertensive Agents; Dyspnea; Female; Humans; Hypertension, Pulmonary; Middle Aged; Multiple Sclerosis; Phenylpropionates; Potassium Channel Blockers; Pyridazines; Tadalafil | 2019 |
Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusion Pumps; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2019 |
Combination therapy improves vascular volume in female rats with pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Female; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Monocrotaline; Phenylpropionates; Pneumonectomy; Pulmonary Artery; Pyridazines; Rats; Rats, Sprague-Dawley; Tadalafil; Vascular Remodeling; Vasoconstriction; Ventricular Dysfunction, Right; X-Ray Microtomography | 2019 |
Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Atrial Remodeling; Cardiac Catheterization; Drug Therapy, Combination; Echocardiography; Epoprostenol; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Risk Reduction Behavior; Tadalafil; Treatment Outcome; Vascular Resistance; Vasodilator Agents; Ventricular Function, Right; Ventricular Remodeling; Walk Test | 2020 |
Fibromuscular dysplasia and coronary artery fistula: links to pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Coronary Artery Disease; Female; Fibromuscular Dysplasia; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sildenafil Citrate; Tadalafil; Vascular Fistula; Vasodilator Agents | 2020 |
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Risk Assessment; Tadalafil; Time Factors; Treatment Outcome; Vasodilator Agents | 2020 |
Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
Topics: Adult; Aged; Antihypertensive Agents; Arterial Pressure; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Lung Transplantation; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pyridazines; Retrospective Studies; Sarcoidosis, Pulmonary; Tadalafil; Treatment Outcome | 2020 |
Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report.
Topics: Adult; Antihypertensive Agents; Diagnostic Errors; Drug Therapy, Combination; High-Throughput Nucleotide Sequencing; Humans; Male; Phenylpropionates; Protein Serine-Threonine Kinases; Pulmonary Arterial Hypertension; Pulmonary Veno-Occlusive Disease; Pyridazines; Tadalafil; Vasodilator Agents | 2021 |
Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Tadalafil; Treatment Outcome | 2022 |